Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Jul;33(4):e13685.
doi: 10.1111/dth.13685. Epub 2020 Jul 14.

The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis

Charan Jeet Arora  1 , Fakhre Alam Khattak  2 , Mohammad Tahir Yousafzai  2 , Bukola Mary Ibitoye  3 , Stephen Shumack  4
Affiliations
Meta-Analysis

The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis

Charan Jeet Arora et al. Dermatol Ther. 2020 Jul.

Abstract

Primary studies have presented conflicting results on the efficacy of Janus kinase (JAK) inhibitors in treating atopic dermatitis. Hence, it is important to determine the summary effect of JAK inhibitors in order to guide the clinical application of this potentially beneficial drug. To determine the efficacy of JAK inhibitors in treating atopic dermatitis in all age groups. A systematic review with meta-analyses of randomized controlled trials (RCTs) reporting on the effect of JAK inhibitors on the signs and symptoms of atopic dermatitis were conducted. Six electronic databases, registries, and search engines (PubMed, Cochrane Central Register of Controlled Trials [CENTRAL], Google Scholar, ScienceDirect, Clinical.gov, and WHO ICTRP) were searched from inception to September, 2019. The search terms include "atopic dermatitis," "eczema," and "Janus kinase inhibitor." The search was restricted to humans. A total of 413 studies were identified through the database search and hand-searching. After the selection process, five RCTs were included in this systematic review. A meta-analysis of three studies showed that JAK inhibitors were effective in reducing Eczema Area and Severity Index (P = .0001) and pruritus scores (P = .0001). JAK inhibitors appear to be effective in treating atopic dermatitis. Future studies should aim to evaluate its cost-effectiveness and availability to patients especially in developing countries.

Keywords: JAK inhibitors; atopic dermatitis.

PubMed Disclaimer

References

REFERENCES

    1. Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175:902-911.
    1. National Institute of Allergy and Infectious Diseasees. Eczema (Atopic Dermatitis). USA: NIH: National Institute of Allergy and Infectious Diseases. 2017. https://www.niaid.nih.gov/diseases-conditions/eczema-atopic-dermatitis. Accessed September 13, 2019.
    1. World Allergy Organisation. Atopic Dermatitis. USA: World Allergy Organisation; 2018. https://www.worldallergy.org/UserFiles/file/WAOAtopicDermatitisInfograph.... Accessed September 13, 2019.
    1. Avena-Woods C. Overview of Atopic Dermatitis. Cranbury, NJ: The American Journal of Managed Care® [AJMC]; 2017. https://www.ajmc.com/journals/supplement/2017/atopic-dermatitis-focusing.... Accessed September 13, 2019].
    1. Hon K-LE, Yong V, Leung T-F. Research statistics in atopic eczema: what disease is this? Ital J Pediatr. 2012;38:26.

Substances

LinkOut - more resources